Monte Rosa Therapeutics · 2 days ago
Senior Research Associate In Vivo
Wonder how qualified you are to the job?
BiotechnologyMedical
Insider Connection @Monte Rosa Therapeutics
Responsibilities
Perform basic and intermediate veterinary technical tasks in mice independently, including compound administration, blood sampling, tumor implantation, and compound formulation preparation.
Optimize and conduct studies to define target biology in mouse models of inflammation and immunity for in vivo, in vitro, and ex vivo applications.
Maintain accurate laboratory records, data summaries, and generate high-quality data reports for management and project teams.
Qualification
Find out how your skills align with this job's requirements. If anything seems off, you can easily click on the tags to select or unselect skills to reflect your actual expertise.
Required
BS/MS in Biology, Pharmacology, Animal Science, or related field with minimum 4 years relevant experience in an industry setting
AALAS certification at the ALAT level is preferred
Uncertified candidates must obtain ALAT certification within 12-18 months or demonstrate substantial progress toward certification
Prior experience necessary in handling compounds for formulation preparation, with a strong emphasis on safety and proficiency in performing necessary calculations
Strong experience in animal handling is required, including compound administration by multiple routes, harvesting tissue and blood samples, and performing necropsy techniques
Preferred
LVT qualification is a plus
Experience with surgical techniques is a plus
Experience in culturing mammalian cell lines is advantageous
Experience with pharmacodynamics assays of mouse tissue, including Western Blotting, ELISA/Mesoscale and flow cytometry is a plus
Company
Monte Rosa Therapeutics
Monte Rosa Therapeutics is a biotechnology company that develops cancer therapeutics that modulate protein degradation pathways.
Funding
Current Stage
Public CompanyTotal Funding
$348.5MKey Investors
Avoro Capital AdvisorsAisling Capital
2024-05-16Post Ipo Equity· $100M
2023-10-26Post Ipo Equity· $25M
2021-06-23IPO· nasdaq:GLUE
Recent News
Investing.com South Africa
2024-06-04
2024-06-04
Company data provided by crunchbase